Last reviewed · How we verify
Immunotherapeutic Agents
At a glance
| Generic name | Immunotherapeutic Agents |
|---|---|
| Also known as | Yervoy, Keytruda, Leukine |
| Sponsor | Gary Onik MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (PHASE2)
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
- Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (PHASE1)
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia (PHASE2, PHASE3)
- Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
- Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial (PHASE2)
- Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes (PHASE2)
- Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunotherapeutic Agents CI brief — competitive landscape report
- Immunotherapeutic Agents updates RSS · CI watch RSS
- Gary Onik MD portfolio CI